Skip to content

A study to see the difference in doses received to tumour and normal organs in patients undergoing prostate radiotherapy by two different techniques Volumetric modulated Arc Therapy (VMAT)and Intensity Modulated radiotherapy(IMRT).

VOLUMETRIC MODULATED ARC THERAPY FOR PROSTATE RADIOTHERAPY: IS THERE ANY SCOPE FOR DOSE ESCALATION ?

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2011/11/002121
Enrollment
30
Registered
2011-11-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- DIAGNOSED CASE OF CA PROSTATE, ELIGIBLE FOR RADICAL RADIOTHERAPY

Interventions

None listed

Sponsors

MedantaThe Medicity
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically proven prostate adenocarcinoma 2. Clinical stage T1-T3, N0-N1, M0 (Patients beyond T1-T2c will be taken after complete androgen blockade for 2 months 3. No prior radical surgery or cryosurgery for prostate cancer

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
To quantitatively compare IMRT and VMAT techniques with regards to dosimetric quality and treatment delivery efficiency in the treatment of prostate cancers eligible to receive RT without violating the organ-at-risk constraints (OARs)Timepoint: To quantitatively compare IMRT and VMAT techniques with regards to dosimetric quality and treatment delivery efficiency in the treatment of prostate cancers eligible to receive RT without violating the organ-at-risk constraints (OARs)

Secondary

MeasureTime frame
To evaluate the Normal tissue complication probability (NTCP) and Tumor control probability (TCP) by dose escalation with VMAT in terms of target coverage and sparing of organs at risk.Timepoint: One year.

Countries

India

Contacts

Public ContactVIKASH KUMAR

Medanta Cancer Institute, Medanta-The Medicity.

tejinder.kataria@medanta.org09810643131

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026